DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Given Consensus Recommendation of “Hold” by Analysts

Shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) have been given an average recommendation of “Hold” by the fourteen ratings firms that are presently covering the firm, Marketbeat reports. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and three have given a buy rating to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $13.8182.

Several analysts have recently commented on XRAY shares. Citigroup started coverage on DENTSPLY SIRONA in a research report on Wednesday, April 15th. They issued a “sell” rating and a $10.00 target price for the company. UBS Group decreased their target price on DENTSPLY SIRONA from $18.00 to $17.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Bank of America raised DENTSPLY SIRONA from a “neutral” rating to a “buy” rating and raised their target price for the stock from $13.00 to $17.00 in a research report on Thursday, February 19th. Barrington Research raised their target price on DENTSPLY SIRONA from $14.00 to $17.00 and gave the stock an “outperform” rating in a research report on Monday, March 2nd. Finally, Robert W. Baird raised their target price on DENTSPLY SIRONA from $12.00 to $14.00 and gave the stock a “neutral” rating in a research report on Friday, February 27th.

DENTSPLY SIRONA Stock Performance

XRAY opened at $10.47 on Monday. The firm has a market cap of $2.10 billion, a PE ratio of -3.32, a P/E/G ratio of 1.22 and a beta of 0.93. The company has a quick ratio of 0.98, a current ratio of 1.53 and a debt-to-equity ratio of 1.52. The business has a fifty day simple moving average of $11.26 and a 200-day simple moving average of $11.74. DENTSPLY SIRONA has a fifty-two week low of $9.40 and a fifty-two week high of $17.09.

DENTSPLY SIRONA (NASDAQ:XRAY) last released its quarterly earnings data on Tuesday, May 5th. The medical instruments supplier reported $0.27 earnings per share for the quarter, missing the consensus estimate of $0.28 by ($0.01). The company had revenue of $880.00 million for the quarter, compared to the consensus estimate of $841.80 million. DENTSPLY SIRONA had a positive return on equity of 18.83% and a negative net margin of 17.06%.The business’s revenue was up .1% compared to the same quarter last year. During the same period in the prior year, the business earned $0.43 earnings per share. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. As a group, equities analysts predict that DENTSPLY SIRONA will post 1.42 EPS for the current fiscal year.

Insider Buying and Selling at DENTSPLY SIRONA

In other DENTSPLY SIRONA news, Director Gregory T. Lucier bought 15,000 shares of the firm’s stock in a transaction dated Monday, March 9th. The stock was acquired at an average price of $12.45 per share, with a total value of $186,750.00. Following the completion of the transaction, the director directly owned 65,000 shares in the company, valued at approximately $809,250. This represents a 30.00% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director James D. Forbes bought 5,000 shares of the firm’s stock in a transaction dated Monday, March 9th. The stock was acquired at an average cost of $12.48 per share, with a total value of $62,400.00. Following the transaction, the director owned 10,000 shares of the company’s stock, valued at $124,800. This trade represents a 100.00% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last ninety days, insiders bought 70,000 shares of company stock valued at $956,437. 0.50% of the stock is currently owned by insiders.

Institutional Trading of DENTSPLY SIRONA

A number of institutional investors have recently bought and sold shares of XRAY. Eurizon Capital SGR S.p.A. acquired a new stake in DENTSPLY SIRONA during the fourth quarter valued at $26,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in DENTSPLY SIRONA during the first quarter valued at $26,000. Huntington National Bank boosted its position in DENTSPLY SIRONA by 292.9% during the third quarter. Huntington National Bank now owns 2,786 shares of the medical instruments supplier’s stock valued at $35,000 after purchasing an additional 2,077 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its position in DENTSPLY SIRONA by 337.9% during the third quarter. Caitong International Asset Management Co. Ltd now owns 2,750 shares of the medical instruments supplier’s stock valued at $35,000 after purchasing an additional 2,122 shares during the last quarter. Finally, Farther Finance Advisors LLC boosted its position in DENTSPLY SIRONA by 119.1% during the fourth quarter. Farther Finance Advisors LLC now owns 3,773 shares of the medical instruments supplier’s stock valued at $43,000 after purchasing an additional 2,051 shares during the last quarter. Institutional investors and hedge funds own 95.70% of the company’s stock.

About DENTSPLY SIRONA

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.